To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Combination HIV-IG/Monoclonal Antibody Dose Neutralizes AIDS Virus URL: http://www.pslgroup.com/dg/196B2.htm Doctor's Guide January 25, 1997
WASHINGTON, Jan. 25, 1997 -- NABI (Nasdaq: NABI) A combination dose of two monoclonal antibodies (Mabs) and HIV-IG(TM), NABI's lead HIV immunotherapeutic, demonstrates significantly enhanced neutralization of the HIV virus. This data was presented today at the Fourth Conference on Retroviruses and Opportunistic Infections. John Mascola, M.D. of the Walter Reed Army Institute of Research and lead scientist on the study noted that a highly synergistic effect between HIV-IG and Mabs 2F5 and 2G12 appeared to be more successful in neutralizing HIV than either single or double combinations of the reagents. "Against most viruses tested, the effect of the combination was synergistic in neutralizing HIV infection of T lymphocytes. The neutralization was found in 13 of the 14 clade B strains of HIV1," Dr. Mascola said. Christine V. Sapan, Ph.D., Director of Scientific Affairs for NABI and co-author of the study, added, "The highly synergistic effect between HIV-IG and monoclonal antibodies suggests that we could use smaller quantities of HIV-IG in a new combination formulation. This new formulation could potentially expand the clinical reach of HIV-IG." David J. Gury, Chairman, President and CEO of NABI, added, "We are encouraged by this data, which represents another significant step in the development of our HIV-IG program." HIV-IG is being studied in two sets of clinical trials being conducted by the National Institutes of Health. HIV-IG, in conjunction with AZT, is undergoing Phase III studies to assess its efficacy in preventing HIV transmission from mother to infant. In a Phase II dosing trial, HIV-IG is being studied to determine its impact on children with AIDS. NABI, a fully integrated biopharmaceutical company, has a broad product portfolio and significant R&D capabilities focused on the development and commercialization of products that prevent and treat autoimmune and infectious diseases. NABI currently has 11 products in its clinical pipeline for indications including HIV; hepatitis viruses; staph infections; and cytomegalovirus. NABI also has two immunotherapeutic products already on the market: H-BIG(R), for the prevention of hepatitis B, and WinRho SD(R), for the treatment of Immune Thrombocytopenic Purpura [ITP, an immune platelet disorder], and for the suppression of Rh isoimmunization. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.